Kreivi Hanna-Riikka, Maasilta Paula, Bachour Adel
Department of Pulmonary Medicine, Heart and Lung Center, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Respir Care. 2016 May;61(5):652-7. doi: 10.4187/respcare.04113. Epub 2016 Jan 5.
The most common adverse effects of CPAP are related to the upper airways. We evaluated upper-airway symptoms before and after a CPAP trial as well as their effect on CPAP adherence. We also evaluated the effect of humidification added to CPAP therapy on upper-airway symptoms.
We followed for 1 y 536 subjects with obstructive sleep apnea scheduled consecutively for CPAP initiation. Subjects completed visual analog questionnaires on nasal stuffiness, rhinorrhea, and mouth dryness (0 = no symptoms, 100 = severe symptoms).
Before CPAP initiation, mean nasal stuffiness score was 29.6 ± 24.9, rhinorrhea score was 16.0 ± 21.7, and mouth dryness score was 43.8 ± 33.1. In subjects who quit CPAP treatment before the 1-y follow-up, the increase in rhinorrhea score during CPAP initiation was significant, 5.3 (95% CI 0.5-9.5, P = .02), and in those using CPAP at 1 y, nasal stuffiness score and mouth dryness score decreased significantly during initiation, -5.1 (95% CI -7.9 to -2.4, P < .001) and -21.2 (-25.5 to -17.4, P < .001). Mouth dryness score decreased significantly with CPAP regardless of humidification: change with humidification, -18.1 (95% CI -22.1 to -14.3), P < .001; change without, -10.5 (95% CI -16.9 to -4.1), P = .002. Humidification also prevented the aggravation of rhinorrhea (change, -0.4 [95% CI -2.6 to 1.9], P = .75) and alleviated nasal stuffiness (change -5.3 [95% CI -7.8 to -2.6], P < .001) with CPAP, whereas its absence induced a significant rise in symptom scores: change in rhinorrhea, 11.5 (95% CI 7.1-16.7), P < .001; change in nasal stuffiness, 8.5 (95% CI 3.9-13.5, P < .001).
The severity of upper-airway symptoms before CPAP does not predict CPAP use at 1 y, whereas CPAP non-users at 1 y had smaller or no alleviation in symptom scores during initiation compared with those who continued CPAP treatment.
持续气道正压通气(CPAP)最常见的不良反应与上呼吸道有关。我们评估了CPAP试验前后的上呼吸道症状及其对CPAP依从性的影响。我们还评估了CPAP治疗中添加湿化对呼吸道症状的影响。
我们对536例阻塞性睡眠呼吸暂停患者进行了为期1年的随访,这些患者连续安排开始使用CPAP。受试者完成了关于鼻充血、鼻溢和口干的视觉模拟问卷(0 = 无症状,100 = 严重症状)。
在开始使用CPAP之前,平均鼻充血评分为29.6±24.9,鼻溢评分为16.0±21.7,口干评分为43.8±33.1。在1年随访前停止CPAP治疗的受试者中,CPAP开始使用期间鼻溢评分的增加显著,为5.3(95%CI 0.5 - 9.5,P = 0.02),而在1年时仍使用CPAP的受试者中,开始使用CPAP期间鼻充血评分和口干评分显著下降,分别为-5.1(95%CI -7.9至-2.4,P < 0.001)和-21.2(-25.5至-1,7.4,P < 0.001)。无论是否进行湿化,CPAP治疗后口干评分均显著下降:湿化组变化为-18.1(95%CI -22.1至-14.3),P < 0.001;未湿化组变化为-10.5(95%CI -16.9至-4.1),P = 0.002。湿化还可防止CPAP治疗引起的鼻溢加重(变化值为-0.4 [95%CI -2.6至1.9],P = 0.75),并减轻鼻充血(变化值为-5.3 [95%CI -7.8至-2.6],P < 0.001),而不进行湿化则会导致症状评分显著升高:鼻溢变化值为11.5(95%CI 7.1 - 16.7),P < 0.001;鼻充血变化值为8.5(95%CI 3.9 - 13.5,P < 0.001)。
CPAP治疗前上呼吸道症状的严重程度不能预测1年时CPAP的使用情况,而与继续接受CPAP治疗的患者相比,1年时未使用CPAP的患者在开始使用CPAP期间症状评分的减轻幅度较小或没有减轻。